Abbott Laboratories (ABT) Stock Price, Quote & News

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement ther...

Industry: Medical Devices

Sector: Healthcare

Phone: 224 667 6100

Website: www.abbott.com

Address:

100 Abbott Park Road, Abbott Park, United States

BillionerOfKing Jun. 26 at 1:48 AM

$ABT Current Stock Price: $93.25 Contracts to trade: $93.0 ABT Jun 26 2026 Call Entry: $0.30 Exit: $0.42 ROI: 40% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

TalkMarkets Jun. 25 at 9:46 PM

The Market Quietly Abandoned The Consumer $ABT $AMGN $COST $SPY $XLV https://talkmarkets.com/article/the-market-quietly-abandoned-the-consumer-1782423958

0 · Reply

iBoughtTheWrongTicker Jun. 25 at 9:07 PM

$ABT alls I need to know is WHO bought, when and how much…ChatGPT says:

0 · Reply

Game_Day Jun. 25 at 8:26 PM

June 25 Thank gd much better today Highlights / alerts $ABT $ABBV $BNC $CRM

0 · Reply

Enjoy_Life_Bro Jun. 25 at 8:23 PM

$ABT Yup

0 · Reply

GettnFibbywIT Jun. 25 at 6:16 PM

$ABT $XLV Abbott Labs - Weekly Chart: ABT’s relative strength versus the S&P 500 appears to be stabilizing at a multi-decade support level, with momentum transitioning from strongly bearish toward neutral. While not yet confirming outperformance vs the broader market, the combination of structural support, diminishing downside pressure, and improving momentum suggests the ratio is in an early basing phase and merits close monitoring for a potential relative rotation:

0 · Reply

DecoderRing Jun. 25 at 4:07 PM

$STXS Some days I feel like management is doing this on purpose. Suppose they have an offer at $3.50 or something (guessing) from $ABT and to avoid investor lawsuits, if they get the price down below $1 they will be able to say they were bought out at a respectable premium.

0 · Reply

Wallstfan Jun. 25 at 3:06 PM

$ABT this is why you buy quality when it’s on sale. Sell tech and buy Abbott.

0 · Reply

1212JM Jun. 25 at 3:01 PM

$ABT who else spent the last two months buying 😏

0 · Reply

FundaTech Jun. 25 at 3:01 PM

$ABT LET’S GOOOOOOOOOO!!!

0 · Reply

3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026

CTAS MCD

Jun 25, 2026, 9:00 AM EDT - 13 hours ago

Abbott hosts conference call for second-quarter earnings

2026-06-24T12:35:52.000Z - 1 day ago

Abbott and ALZpath announce license agreement

Jun 24, 2026, 8:30 AM EDT - 1 day ago

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing

Jun 24, 2026, 7:36 AM EDT - 1 day ago

ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test

2026-06-23T22:53:44.000Z - 2 days ago

3 Dividend Aristocrat Stocks Wall Street Loves Right Now — June 23, 2026

NEE WMT

Jun 23, 2026, 1:34 PM EDT - 2 days ago

Missouri appeals court won't send Abbott's appeal of $495 million preterm baby formula verdict to higher court

Jun 22, 2026, 12:00 PM EDT - 3 days ago

New Similac® survey finds social media pressure to be "perfect" is fueling a shift toward authenticity for the next generation of parents

Jun 18, 2026, 2:14 PM EDT - 7 days ago

Living Longer Is Big Business. These Stocks Will Benefit.

DXCM GH HIMS PLNT

Jun 17, 2026, 12:30 PM EDT - 8 days ago

The Healthcare M&A Wave

ALNY AMGN AMRX ANTX AZN BDX BEAM

2026-06-17T10:57:22.000Z - 8 days ago

Citi sum-of-the-parts analysis shows Abbott share upside

Jun 12, 2026, 2:29 PM EDT - 13 days ago

Abbott declares 410th consecutive quarterly dividend

2026-06-12T10:41:20.000Z - 13 days ago

Abbott price target lowered to $102 from $120 at BofA

Jun 8, 2026, 9:00 AM EDT - 17 days ago

New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers

2026-06-07T22:10:06.000Z - 18 days ago

Abbott announces new data on DKA for people with Type 1, Type 2 diabetes

Jun 6, 2026, 10:01 AM EDT - 19 days ago

The U.S. stock market is facing historic downside risk — these 10 low-volatility stocks can protect your portfolio

GIS KMB MDT O PPL ROP SNA

Jun 6, 2026, 9:00 AM EDT - 19 days ago

New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

Jun 4, 2026, 3:46 PM EDT - 21 days ago

Abbott Labs must face lawsuit over PediaSure children's growth claims

2026-06-03T11:49:56.000Z - 22 days ago

MiniMed announces expanded ketone sensor agreement with Abbott

MMED

2026-05-27T13:04:49.000Z - 4 weeks ago

Abbott secures CE Mark for Libre Duo, Libre Duo 10 Day

May 27, 2026, 9:00 AM EDT - 4 weeks ago

Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

May 27, 2026, 7:01 AM EDT - 4 weeks ago

ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening

May 26, 2026, 9:00 AM EDT - 4 weeks ago

Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026

2026-05-22T20:00:19.000Z - 4 weeks ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 15%+ Upside, 5/22/26

AMZN NEE WMT

May 15, 2026, 1:00 AM EDT - 5 weeks ago

Even a High-Priced Market Has Bargains. 10 Undervalued Blue-Chip Stocks.

ACN DHR HD MCD MDT MKC RSG

Apr 28, 2026, 9:00 AM EDT - 2 months ago

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Apr 25, 2026, 12:30 PM EDT - 2 months ago

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

Apr 17, 2026, 3:30 PM EDT - 2 months ago

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Apr 16, 2026, 11:22 AM EDT - 2 months ago

Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales

Apr 16, 2026, 9:00 AM EDT - 2 months ago

Abbott Laboratories Earnings Call Transcript: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 2 months ago

Abbott Laboratories Earnings release: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 2 months ago

Abbott Laboratories Slides: Q1 2026

Apr 16, 2026, 9:00 AM EDT - 2 months ago

Abbott Laboratories Quarterly report: Q1 2026

Apr 16, 2026, 8:05 AM EDT - 2 months ago

Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.

Apr 16, 2026, 7:33 AM EDT - 2 months ago

Abbott first-quarter results beat on cancer diagnostics, medical device strength

Apr 16, 2026, 7:30 AM EDT - 2 months ago

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Apr 9, 2026, 10:16 PM EDT - 2 months ago

Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

Apr 9, 2026, 9:00 AM EDT - 2 months ago

New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

Mar 30, 2026, 9:00 AM EDT - 3 months ago

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

Mar 26, 2026, 9:00 AM EDT - 3 months ago

Abbott hosts conference call for first-quarter earnings

Mar 24, 2026, 8:00 AM EDT - 3 months ago

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

Mar 23, 2026, 8:50 AM EDT - 3 months ago

Abbott completes acquisition of Exact Sciences

Mar 20, 2026, 9:00 AM EDT - 3 months ago

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Mar 13, 2026, 2:17 PM EDT - 3 months ago

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Mar 13, 2026, 8:00 AM EDT - 3 months ago

Abbott Laboratories Proxy statement: Proxy Filing

Mar 13, 2026, 8:00 AM EDT - 3 months ago

Abbott Laboratories Proxy statement: Proxy Filing

Mar 12, 2026, 8:00 AM EDT - 3 months ago

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Feb 20, 2026, 4:05 PM EST - 4 months ago

Exact Sciences Stockholders Approve Acquisition by Abbott

EXAS

Feb 20, 2026, 11:38 AM EST - 4 months ago

Abbott declares 409th consecutive quarterly dividend

Feb 17, 2026, 11:32 AM EST - 4 months ago

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Feb 12, 2026, 8:05 AM EST - 4 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ADBE AMGN AVGO BAC BMY COF

Feb 6, 2026, 8:00 AM EST - 4 months ago

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Feb 4, 2026, 10:49 AM EST - 5 months ago

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Jan 23, 2026, 9:35 AM EST - 5 months ago

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 6:43 AM EST - 5 months ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 22, 2026, 2:31 PM EST - 5 months ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 11:00 AM EST - 5 months ago

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

MRNA PG

Jan 22, 2026, 9:53 AM EST - 5 months ago

Cramer's Mad Dash: Abbott Labs

Jan 22, 2026, 9:00 AM EST - 5 months ago

Abbott Laboratories Earnings Call Transcript: Q4 2025

Jan 22, 2026, 9:00 AM EST - 5 months ago

Abbott Laboratories Annual report: Q4 2025

Jan 22, 2026, 9:00 AM EST - 5 months ago

Abbott Laboratories Earnings release: Q4 2025

Jan 22, 2026, 9:00 AM EST - 5 months ago

Abbott Laboratories Slides: Q4 2025

Jan 22, 2026, 7:49 AM EST - 5 months ago

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Jan 22, 2026, 7:34 AM EST - 5 months ago

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Jan 22, 2026, 7:30 AM EST - 5 months ago

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Jan 20, 2026, 9:00 AM EST - 5 months ago

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Jan 7, 2026, 8:00 AM EST - 6 months ago

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Jan 5, 2026, 4:30 PM EST - 6 months ago

Abbott hosts conference call for fourth-quarter earnings

BillionerOfKing Jun. 26 at 1:48 AM

0 · Reply

TalkMarkets Jun. 25 at 9:46 PM

The Market Quietly Abandoned The Consumer $ABT $AMGN $COST $SPY $XLV https://talkmarkets.com/article/the-market-quietly-abandoned-the-consumer-1782423958

0 · Reply

iBoughtTheWrongTicker Jun. 25 at 9:07 PM

$ABT alls I need to know is WHO bought, when and how much…ChatGPT says:

0 · Reply

Game_Day Jun. 25 at 8:26 PM

June 25 Thank gd much better today Highlights / alerts $ABT $ABBV $BNC $CRM

0 · Reply

Enjoy_Life_Bro Jun. 25 at 8:23 PM

$ABT Yup

0 · Reply

GettnFibbywIT Jun. 25 at 6:16 PM

0 · Reply

DecoderRing Jun. 25 at 4:07 PM

0 · Reply

Wallstfan Jun. 25 at 3:06 PM

$ABT this is why you buy quality when it’s on sale. Sell tech and buy Abbott.

0 · Reply

1212JM Jun. 25 at 3:01 PM

$ABT who else spent the last two months buying 😏

0 · Reply

FundaTech Jun. 25 at 3:01 PM

$ABT LET’S GOOOOOOOOOO!!!

0 · Reply

DBRGLong Jun. 25 at 2:35 PM

$ABT some profit taking from TWST over the past day, & have been reinvesting here in ABT, w/ an average cost of $92. I think we are poised for a terrific rebound, at least towards $120+, between now & year end. Good luck my fellow ABT longs.

0 · Reply

Game_Day Jun. 25 at 1:42 PM

Great watch today / alerted $ABT $ABBV $BNC

0 · Reply

FundaTech Jun. 25 at 1:40 PM

$ABT Good morning guys! Make sure to use your Libre and drink your Ensure!

0 · Reply

KappaKeepoKuppo Jun. 24 at 9:01 PM

$ABT managed to pump at open and then slowly bleed into the red at the close. What is this stock man, haha

1 · Reply

Thamb19 Jun. 24 at 7:09 PM

$BSX playing this arbitrage between BSX and $ABT

0 · Reply

macrossluvsrobotech Jun. 24 at 3:07 PM

$LXRX — two H2 2026 catalysts converging that the market is missing. Zynquista (sotagliflozin) T1D NDA resubmission is on track for mid-2026 per Q1 earnings, with potential FDA approval this year. The gating factor: STENO1 must generate adequate DKA safety data — not clear a numeric threshold, but characterize DKA frequency, severity, and clinical management well enough to support labeling. Simultaneously, Abbott’s Libre Duo just received CE Mark (May 27) — the world’s first continuous glucose + ketone monitor. FDA decision expected H2 2026. Explicitly designed for SGLT inhibitor users at elevated DKA risk. Translation: the exact tool needed to manage sotagliflozin’s DKA risk profile in T1D is arriving in the same regulatory window as the Zynquista resubmission. Real-time ketone monitoring makes REMS design and labeling far more tractable. The infrastructure that de-risks the drug is being built in real time. Watch STENO1 data + Abbott FDA clearance. 🔬 $LXRX $ABT

0 · Reply

Thamb19 Jun. 24 at 1:53 PM

$BSX breaking resistance... $ABT $MDT $IHI safety play for $SOXX winners when soxx will sell off

1 · Reply

SuperGreenToday Jun. 24 at 3:32 AM

$ABT Share Price: $90.51 Contract Selected: Jul 17, 2026 $90 Calls Buy Zone: $2.63 – $3.26 Target Zone: $4.77 – $5.83 Potential Upside: 71% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Enjoy_Life_Bro Jun. 23 at 5:25 PM

$ABT Needs to hold $90

0 · Reply

Jamoke13 Jun. 23 at 3:31 PM

$ABT $MKC $PRMW $KBR my value plays. anyone have thoughts on em

2 · Reply

FundaTech Jun. 23 at 2:41 PM

$ABT Like a warm drink it seeps into your soul.

0 · Reply

Jamoke13 Jun. 23 at 2:13 PM

$ABT this bottomed, 100+ soon

0 · Reply

Market Cap	157.62B
Revenue (ttm)	44.33B
Net Income (ttm)	6.52B
EPS (ttm)	N/A
PE Ratio	17.38
Forward PE	16.53
Profit Margin	14.72%
Debt to Equity Ratio	0.65

Volume	16,708,600
Avg Vol	13,763,712
Day's Range	N/A - N/A
Shares Out	1.74B
Stochastic %K	82%
Beta	0.63
Analysts	Strong Sell
Price Target	$117.92